Image Source : fermentabiotech.com
Fermenta Biotech Ltd’s board has approved a ₹110 crore capital expenditure plan to expand its Dahej manufacturing facility. The investment will support production of plant-based Vitamin D3, green chemistry enzymes, and Vitamin D3 derivatives, aligning with the company’s focus on sustainable biotechnology and next-generation nutritional ingredients.
Show more
Fermenta Biotech Ltd announced board approval for a ₹110 crore expansion project at its Dahej facility in Gujarat. The capex will drive the company’s diversification into plant-based and environmentally sustainable products, enhancing capacity for biotechnology-driven health and nutrition solutions.
Key Highlights:
-
The new investment targets production of plant-based Vitamin D3, a sustainable alternative to traditional animal-based sources.
-
It also covers manufacturing of green chemistry enzymes and Vitamin D3 derivatives, leveraging bio-based technologies.
-
The project aligns with Fermenta’s strategy to consolidate its leadership in the nutraceutical segment and tap global demand for clean-label ingredients.
-
The Dahej site will serve as a center for advanced biotechnological research and scale-up operations.
-
The capex will be funded through internal accruals and/or debt, with implementation expected in phased stages.
-
Fermenta Biotech’s move underscores its shift toward sustainable innovation in health and wellness products.
Source: Company filing with BSE and NSE; Fermenta Biotech Ltd regulatory announcement.
Stay Ahead – Explore Now!
ixigo’s Journey Hits a Profit Peak: Q4 Revenue Takes Off!
Advertisement
Advertisement